Floatz logo

Cytosin-Arabinosid

Primary Central Nervous System Lymphoma (PCNSL)

FengYan JinN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

73 Active assets in the Primary Central Nervous System Lymphoma (PCNSL) cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 4BBB
(+)-VINCRISTINE
Ono Pharmaceutical Co., Ltd.
Phase 4BBB
METHOTREXATE
Assistance Publique Hopitaux De Marseille
Phase 4BB
Orelabrutinib
The First Affiliated Hospital with Nanjing Medical University
Phase 3BB
Idarubicine
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 4BB

View all 50 →

Same molecule, other indications

Cytosin-Arabinosid is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
82 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →